Shuttle Pharma expands Phase 2 glioblastoma trial; adds sites, extends timeline through Jan 2026

Shuttle Pharmaceuticals Holdings, Inc.

Change Order with Theradex increases Phase 2 patients from 15 to 16 and sites from 4 to 6.
Total budget limited to $5,308,294; covers activities through 31 January 2026.
Protocol amendments versions 2.0 and 3.0 added; safety teleconferences expanded for medical monitor review.
Two sites (UNC and Georgetown) activated earlier than anticipated, driving budget increase.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.